CD4 and neoplasm: Expansion of an ICOS+ TH1-like CD4+ effector subset was observed in response to CTLA4 blockade; therefore, TH cells, particularly the TH1 cells, are also pivotal players in T-cell mediated anti-tumor immunity and can respond to immunotherapy (Wei et al., 2017).